Back to News
Market Impact: 0.22
Evotec Biologics Begins Phase 1 Trial For Orthopoxvirus Antibody Program
Source: Nasdaq
Healthcare & BiotechProduct Launches
Evotec has initiated a first-in-human Phase 1 trial of JST-018, an investigational monoclonal-antibody cocktail targeting orthopoxviruses. The trial marks an early clinical-development milestone for the program, but efficacy, safety, regulatory approval, and commercial potential remain unproven.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
EVO0.65
More News
- Samsung works to draw iPhone users to its foldables even as Apple enters the market
- Oil Tops $100 on Supply Fears, Apple Faces a Big Test
- Nano-X Imaging (NNOX) Q2 2026 Earnings Call Transcript
- Chewy (CHWY) Q2 2026 Earnings Call Transcript
- Kaplan Fox Encourages Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to Contact the Firm to Learn About Their Legal Rights
- Apple drops its folding iPhone. Our first reaction, plus the other key launch news